Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
How clinicians impact patient outcomes in psychedelic therapy, Why it is time for the UK to change laws on psychedelics, How to untangle the ethics of psychedelic care
Trial to investigate psychedelic candidate for alcohol use disorder, Positive results from BPL-003 in Treatment Resistant Depression, Exploring the latest updates in psychedelic medicine.
Ayahuasca retreats associated with increases in nature-relatedness, What's happening for psychedelics in Europe?, JP Morgan in discussions with psychedelics companies
MDMA for PTSD receives priority review for New Drug Application, Psychedelic experiences linked with improved sexual function, Sovereign wealth funds in talks to fund biotech groups harnessing psychedelics.
Psilocybin therapy for end-of-life care supported by 79% of Canadians, Independent UK body issues response on psychedelics for anxiety, Bill aims to legalise psychedelic-assisted therapy in California.
Non-SRI patients experience positive therapeutic effects of psychedelics, Microdosing psilocybin may help compulsive behaviours, Key legal factors to consider for psychedelic clinical trials.
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Subscribe to the Psychedelics Newsletter
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
